Citations

Clear

390 citation(s) found for "Loftus, E".

The Pyk2 FERM domain as a target to inhibit glioma migration
Loftus, Joseph C. , Tran, Nhan L. , Kloss, Jean , Viso, Carole, Yang, Zhongbo , Berens, Michael E. , Lipinski, Christopher A. , Tran, Nhan L

Mayo Clinic

Molecular Cancer Therapeutics | June 10, 2009 | Volume: 8 | Issue: 6 | Pages: 1505-1514

10.1158/1535-7163.mct-08-1055 | PMID 19509258 Get It

Abstract The invasion of malignant glioma cells into the surrounding normal brain precludes effective clinical treatment. In this report, we investigated the role of the NH2-terminal FERM domain in the regulation of the promigratory function of Pyk2. We report that the substitution of residues that constitute a small cleft on the surface of the F3 module of the FERM domain do not significantly alter Pyk2 expression but result in the loss of Pyk2 phosphorylation. A monoclonal antibody, designated 12A10, specifically targeting the Pyk2 FERM domain was generated and recognizes an epitope located on the β5C-α1C surface of the F3 module of the FERM domain. Amino acid substitutions in the F3 module that resulted in the loss of Pyk2 phosphorylation also inhibited the binding of 12A10, suggesting that the 12A10 epitope overlaps a site that plays a role in Pyk2 activity. Conjugation of 12A10 to a membrane transport peptide led to intracellular accumulation and inhibition of glioma cell migration in a concentration-dependent manner. A single chain Fv fragment of 12A10 was stable when expressed in the intracellular environment, interacted directly with Pyk2, reduced Pyk2 phosphorylation, and inhibited glioma cell migration in vitro. Stable intracellular expression of the 12A10 scFv significantly extended survival in a glioma xenograft model. Together, these data substantiate a central role for the FERM domain in regulation of Pyk2 activity and identify the F3 module as a novel target to inhibit Pyk2 activity and inhibit glioma progression. [Mol Cancer Ther 2009;8(6):1505–14]
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota
Pardi, Darrell S. , Loftus, Edward V. , Smyrk, Thomas C. , Kammer, Patricia P., Tremaine, William J., Schleck, C. D., Harmsen, William S. , Zinsmeister, Alan R., Melton, L. Joseph, Sandborn, William J. , Loftus, Edward V

Mayo Clinic

Gut | November 29, 2006 | Volume: 56 | Issue: 4 | Pages: 504-508

10.1136/gut.2006.105890 | PMID 17135309 Get It

Objective: Although the epidemiology of microscopic colitis has been described in Europe, no such data exist from North America. We studied the incidence, prevalence and temporal trends of microscopic colitis in a geographically defined US population. Design and setting: In this population based cohort study, residents of Olmsted County, Minnesota, with a new diagnosis of microscopic colitis, and all who had colon biopsies for evaluation of diarrhoea, between 1 January 1985 and 31 December 2001 were identified. Biopsies were reviewed for confirmation (cases) and to identify missed cases (diarrhoea biopsies). Main outcome measures: Incidence rates, age and sex adjusted to the 2000 US white population. Poisson regression assessed the association of calendar period, age and sex with incidence. Results: We identified 130 incident cases for an overall rate of 8.6 cases per 100 000 person-years. There was a significant secular trend, with incidence increasing from 1.1 per 100 000 early in the study to 19.6 per 100 000 by the end (p<0.001). Rates increased with age (p<0.001). By subtype, the incidence was 3.1 per 100 000 for collagenous colitis and 5.5 per 100 000 for lymphocytic colitis. Collagenous colitis was associated with female sex (p<0.001) but lymphocytic colitis was not. Prevalence (per 100 000 persons) on 31 December 2001 was 103.0 (39.3 for collagenous colitis and 63.7 for lymphocytic colitis). Conclusions: The incidence of microscopic colitis has increased significantly over time, and by the end of the study, the incidence and prevalence were significantly higher than reported previously. Microscopic colitis is associated with older age, and collagenous colitis is associated with female sex.
Increased Fibroblast Growth Factor-Inducible 14 Expression Levels Promote Glioma Cell Invasion via Rac1 and Nuclear Factor-κB and Correlate with Poor Patient Outcome
Tran, Nhan L. , McDonough, Wendy S., Savitch, Benjamin A., Ensign, Shannon P. Fortin , Winkles, Jeffrey A. , Symons, Marc , Cunliffe, Heather E. , Hoelzinger, Dominique B. , Rennert, Jessica L., Burkly, Linda C. , Loftus, Joseph C. , Ensign, Shannon P. Fortin , Nakada, Mitsutoshi , Hostetter, Galen H. , Michaelson, Jennifer S. , Lipinski, Christopher A. , Mariani, Luigi , Berens, Michael E. , Tran, Nhan L

Mayo Clinic

Cancer Research | October 3, 2006 | Volume: 66 | Issue: 19 | Pages: 9535-9542

10.1158/0008-5472.can-06-0418 | PMID 17018610 Get It

Abstract Glial tumors progress to malignant grades by heightened proliferation and relentless dispersion throughout the central nervous system. Understanding genetic and biochemical processes that foster these behaviors is likely to reveal specific and effective targets for therapeutic intervention. Our current report shows that the fibroblast growth factor-inducible 14 (Fn14), a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed at high levels in migrating glioma cells in vitro and invading glioma cells in vivo. Forced Fn14 overexpression stimulates glioma cell migration and invasion, and depletion of Rac1 by small interfering RNA inhibits this cellular response. Activation of Fn14 signaling by the ligand TNF-like weak inducer of apoptosis (TWEAK) stimulates migration and up-regulates expression of Fn14; this TWEAK effect requires Rac1 and nuclear factor-κB (NF-κB) activity. The Fn14 promoter region contains NF-κB binding sites, which mediate positive feedback causing sustained overexpression of Fn14 and enduring glioma cell invasion. Furthermore, Fn14 gene expression levels increase with glioma grade and inversely correlate with patient survival. These results show that the Fn14 cascade operates as a positive feedback mechanism for elevated and sustained Fn14 expression. Such a feedback loop argues for aggressive targeting of the Fn14 axis as a unique and specific driver of glioma malignant behavior. (Cancer Res 2006; 66(19): 9535-42)
Bringing Molecular Biology to Bear on Adhesion Prevention: Postsurgical Adhesion Reduction Using Intraperitoneal Inoculation of Hyaluronic Acid–Inducing Adenoviral Vector in a Murine Model
Hammer, Robert A., Morse, Abraham N. , Cornella, Jeffrey L. , Keller, Rebecca S., Hentz, Joseph G. , McDonald, John A., Loftus, Joseph C.

Mayo Clinic

Journal of Gynecologic Surgery | July 13, 2006 | Volume: 22 | Issue: 1 | Pages: 7-18

10.1089/gyn.2006.22.7 Get It

Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein
祐子, 森村, Solem, C A, Sandborn, W J, Booya, F, Loftus, E V, Harmsen, W S, Zinsmeister, A R, Bodily, K D, Fletcher, J G, Loftus, Edward V. , Solem, C A, Sandborn, W J, Booya, F, Loftus, E V, Harmsen, W S, Zinsmeister, A R, Bodily, K D, Fletcher, J G, Loftus, Edward V

Mayo Clinic

Gut | April 28, 2006 | Volume: 55 | Issue: 11 | Pages: 1561-1567

10.1136/gut.2005.084301 | PMID 16648154 Get It

Background: Few studies have correlated computed tomography (CT) enterography findings with endoscopic severity and C reactive protein (CRP) concentrations. Aim: To examine whether small bowel inflammation at CT enterography correlates with endoscopic severity and CRP in patients with Crohn’s disease (CD). Methods: CT enterography datasets from 143 CD patients undergoing ileoscopy were examined for three different CT parameters: CT bowel enhancement, as defined by the ratio of terminal ileal versus control ileal loop attenuation; vascular enlargement of the vasa recta (“the comb sign”); and mesenteric fat density. Correlations between CT scan parameters, endoscopy, and histology severity scores, and CRP were assessed using Spearman’s rank correlation and logistic regression. Results: Endoscopic score was significantly correlated with CT bowel enhancement, comb sign, and fat density (Spearman correlation coefficients 0.33–0.39; p<0.001). Correlations with histological inflammation were strongest for bowel enhancement (r = 0.34–0.38; p<0.001). CRP was elevated in patients with increased fat density versus those with increased bowel enhancement only (median 0.96 v 0.23, p = 0.002). CRP did not differ significantly between patients without evidence of active Crohn’s and those with bowel enhancement and endoscopic inflammation not involving the perienteric tissues by CT (median 0.24 v 0.36; p = 0.38). Conclusion: Quantitative measures of bowel enhancement at CT enterography correlate with endoscopic and histological severity. CRP correlates with radiological findings of perienteric inflammation (increased fat density), but not of inflammation limited to the small bowel wall, underscoring the potential role of perienteric inflammation in CRP response in CD.
Validation of a Mouse Adhesion Reduction Model Using Seprafilm ®
Morse, Abraham N. , Hammer, Robert A., Cornella, Jeffrey L. , Loftus, Joseph C.

Mayo Clinic

Journal of Gynecologic Surgery | January 10, 2006 | Volume: 21 | Issue: 4 | Pages: 147-153

10.1089/gyn.2005.21.147 Get It

Targeted Measles Virus Vector Displaying Echistatin Infects Endothelial Cells via αvβ3 and Leads to Tumor Regression
Hallak, Louay K. , Storgard, Chris, Loftus, Joseph C. , Merchan, Jaime R. , Russell, Stephen J.

Mayo Clinic

Cancer Research | September 15, 2005 | Volume: 65 | Issue: 12 | Pages: 5292-5300

10.1158/0008-5472.can-04-2879 | PMID 15958576 Get It

Abstract Targeting tumor-associated vascular endothelium by replication-competent viral vectors is a promising strategy for cancer gene therapy. Here we describe the development of a viral vector based on the Edmonston vaccine strain of measles virus targeted to integrin αvβ3, which is expressed abundantly on activated but not quiescent vascular endothelium. We displayed a disintegrin, M28L echistatin that binds with a high affinity to integrin αvβ3 on the COOH terminus of the viral attachment (H) protein and rescued the replication-competent recombinant virus by reverse genetics. The new targeted virus was named measles virus echistatin vector (MV-ERV). Its native binding to CD46 was purposefully retained to allow virus infection of tumor cells expressing this receptor. MV-ERV correctly displayed echistatin on the outer surface of its envelope and produced interesting ring formation phenomena due to cell detachment upon infection of susceptible Vero cells in vitro. MV-ERV grew to 106 plaque-forming units/mL, slightly lower than the parental Edmonston strain of measles virus (MV-Edm), but it selectively infected Chinese hamster ovary cells expressing integrin αvβ3. It also selectively infected both bovine and human endothelial cells on matrigels and unlike MV-Edm, MV-ERV infected newly formed blood vessels in chorioallantoic membrane assays. In animal models, MV-ERV but not the control MV-Edm caused the regression of s.c. xenografts of resistant multiple myeloma tumors (MM1) in severe combined immunodeficient mice. The tumors were either completely eradicated or their growth was significantly retarded. The specificity, potency, and feasibility of MV-ERV infection clearly show the potential use of MV-ERV in gene therapy for targeting tumor-associated vasculature for the treatment of solid tumors.
In vitro selection of fibronectin gain-of-function mutations
Tani, P, Loftus, Joseph C. , Bowditch, Ron D.

Mayo Clinic

Biochemical Journal | July 28, 2002 | Volume: 365 | Issue: 1 | Pages: 287-294

10.1042/bj20020067 | PMID 12071856 Get It

Directed protein evolution, which employs a combination of random mutagenesis, phage display, and in vitro selection, was used to identify second-site suppressors of the fibronectin (Fn) cell binding domain mutation Asp1495Ala (RGA). The mutations in the Fn 9th (3fn9) and 10th (3fn10) type III repeats obtained after selection on purified integrins αIIbβ3(D119Y) and α5β1 are reported. The 3fn9–10(D1495A) phage with substitution mutations at Asp1418, which is located within the linker region between 3fn9 and 3fn10, enhanced binding to the integrins αIIbβ3 and α5β1, but not αvβ3. The substitution mutations identified at residue Asp1418 were introduced into the native recombinant 3fn9–10 sequence and found to augment binding to αIIbβ3, demonstrating that the observed gain-of-function phenotype was independent of the multivalent character of the phage. These results support the following conclusions. First, regions of Fn in addition to the RGD loop are in close proximity to αIIbβ3 and α5β1 and are capable of participating in the binding to these integrins. Secondly, the conformational relationship between the 3fn9 and 3fn10 modules may be an important factor in the binding of Fn to these two integrins. Thirdly, other altered properties of Fn-integrin interactions, such as integrin specificity, may also be selected. This is the first description of Fn mutations that augment binding to integrins. The ability to select for particular phenotypes in vitro and the subsequent characterization of these mutations should further our understanding of the molecular details involved in the association of integrins and their ligands. Additionally, these higher-affinity 3fn9–10 ligands provide a starting point for further in vitro evolution and engineering of integrin-specific modules.
Autoantibodies to αIIbβ3 in patients with chronic immune thrombocytopenic purpura bind primarily to epitopes on αIIb
McMillan, Robert, Lopez‐Dee, Jennifer, Loftus, Joseph C.

Mayo Clinic

Blood | July 27, 2002 | Volume: 97 | Issue: 7 | Pages: 2171-2172

10.1182/blood.v97.7.2171 | PMID 11264188 Get It

Abstract Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disease caused by platelet destruction resulting from autoantibodies against platelet surface proteins, particularly platelet glycoprotein IIb/IIIa (αIIbβ3). To localize the auto-epitopes on platelet αIIbβ3, the binding of autoantibodies to Chinese hamster ovary (CHO) cells expressing either αIIbβ3 or αvβ3was studied. Thirteen of 14 ITP autoantibodies bound only to CHO cells expressing αIIbβ3. Because these 2 integrins have the same beta chain (β3), these results show that most epitopes in chronic ITP are dependent on the presence of glycoprotein αIIb.
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
Lowry, Philip W., Franklin, C L, Weaver, A L, Szumlanski, C L, Mays, D C, Loftus, E V, Tremaine, W J, Lipsky, J J, Weinshilboum, R M, Sandborn, W J, Loftus, Edward V. , Franklin, C L, Weaver, A L, Szumlanski, C L, Mays, D C, Loftus, E V, Tremaine, W J, Lipsky, J J, Weinshilboum, R M, Sandborn, W J, Loftus, Edward V

Mayo Clinic

Gut | July 27, 2002 | Volume: 49 | Issue: 5 | Pages: 656-664

10.1136/gut.49.5.656 | PMID 11600468 Get It

AIM We evaluated the effect of coadministration of sulphasalazine, mesalamine, and balsalazide on the pharmacokinetics and pharmacodynamics of azathioprine and 6-mercaptopurine. METHODS Thirty four patients with Crohn's disease receiving azathioprine or 6-mercaptopurine were enrolled in an eight week non-randomised parallel group drug interaction study and treated with mesalamine 4 g/day, sulphasalazine 4 g/day, or balsalazide 6.75 g/day. The primary outcome measure was the occurrence of clinically important leucopenia during the study, defined separately as total leucocyte counts <3.0 x 10 9 /l and ⩽3.5×10 9 /l. Whole blood 6-thioguanine nucleotide concentrations were determined. RESULTS Three patients could not be evaluated for the primary outcome measure. In the remaining 31 patients, the frequency of total leucocyte counts <3.0 and ⩽3.5 were: 1/10 and 5/10 in the mesalamine group; 1/11 and 6/11 in the sulphasalazine group; and 0/10 and 2/10 in the balsalazide group. There were significant increases in mean whole blood 6-thioguanine nucleotide concentrations from baseline at most time points in the mesalamine and sulphasalazine groups but not in the balsalazide group. CONCLUSIONS In patients with Crohn's disease receiving azathioprine or 6-mercaptopurine, coadministration of mesalamine, sulphasalazine, and possibly balsalazide results in an increase in whole blood 6-thioguanine nucleotide concentrations and a high frequency of leucopenia.